Abstract 5432: Mutation of Three Amino Acids in the Disulfide-Ring of a CNP Based Chimeric Natriuretic Peptide Alters its Vascular Properties

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Horng H Chen ◽  
Brenda K Huntley ◽  
Candace Y Lee ◽  
Fernando L Martin ◽  
John A Schirger ◽  
...  
Keyword(s):  
Amino Acid ◽  
Natriuretic Peptide ◽  
Right Atrial ◽  
Bolus Administration ◽  
Amino Acid Peptide ◽  
Arterial Blood ◽  
C Terminus ◽  
Cardiac Unloading

BACKGROUND: C-type natriuretic peptide (CNP) is a 22-amino-acid peptide produced mainly in the endothelium with potent cardiac unloading and modest blood pressure lowering actions, but minimal renal actions. Based on our previous knowledge, we recently fused a 6 aa sequence from BNP to the C-terminus and a 5 aa sequence from ANP to the N-terminus of CNP. This novel hybrid peptide, CBA-NP, has cardiac unloading actions and mild hypotensive effects similar to CNP. Importantly however, the N and C terminus alterations resulted in potent renal excretory actions. here we test the hypothesis that the 3 aa GSM 15–17 in the disulfide-ring mediate the vascular and hypotensive actions. We therefore mutated GSM 15–17 to REA 15–17 , which we named ABC-NP and compared its in vivo and in vitro actions to CBA-NP. METHODS: We determined the cardiorenal and humoral actions of intravenous bolus administration of CBA-NP (n=5) and ABC-NP (n=5) at 25 microgram/Kg in 2 separate group of normal anesthetized dogs. We also assessed the cGMP response of both peptides in human aortic endothelial cells (HAEC), human cardiac fibroblast (HCF) and isolated canine glomeruli. * p<0.05 RESULTS: IV bolus administration of CBA-NP and ABC-NP resulted in diuresis* and natriuresis*. There was a significant decrease in mean arterial blood (MAP) pressure with CBA-NP (126±6 to113±7 mmHg*) but no change with ABC-NP(126±8 to126±8 mmHg) . In addition, the reduction in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) was significantly greater with CBA-NP as compared to ABC-NP. cGMP generation in HAEC and HCF was minimal with ABC-NP and was significantly higher with CBA-NP*. In contrast, cGMP generation was similar in isolated glomeruli between the two peptides. CONCLUSION: Our studies demonstrates that mutation of three amino acid (aa) residues within the CNP ring of CBA-NP from GSM 15–17 to REA alters the vascular but not the renal excretory properties. Hence by this strategic mutation within the ring of CBA-NP, we have designed a renal specific peptide ABC-NP resulting in new sequence specific functional information which can be used to design organ specific therapeutic peptides with unique properties tailored for a specific disease state.

Regulation of SulA cleavage by Lon protease by the C-terminal amino acid of SulA, histidine

2001 ◽  
Vol 358 (2) ◽  
pp. 473-480 ◽  
Author(s):  
Yoshiyuki ISHII ◽  
Fumio AMANO
Keyword(s):  
Amino Acid ◽  
Protein A ◽  
Lon Protease ◽  
Histidine Residue ◽  
High Accumulation ◽  
C Terminus ◽  
A Cell ◽  
Cell Division Inhibitor

SulA protein, a cell division inhibitor in Escherichia coli, is degraded by Lon protease. The C-terminal eight residues of SulA have been shown to be recognized by Lon; however, it remains to be elucidated which amino acid in the C-terminus of SulA is critical for the recognition of SulA by Lon. To clarify this point, we constructed mutants of SulA with changes in the C-terminal residues, and examined the accumulation and stability of the resulting mutant SulA proteins in vivo. Substitution of the extreme C-terminal histidine residue with another amino acid led to marked accumulation and high stability of SulA in lon+ cells. A SulA mutant in which the C-terminal eight residues were deleted (SulAC161) showed high accumulation and stability, but the addition of histidine to the C-terminus of SulAC161 (SulAC161+H) made it labile. Similarly, SulAC161+H fused to maltose-binding protein (MBP–SulAC161+H) formed a tight complex with and was degraded rapidly by Lon in vitro. Histidine competitively inhibited the degradation of MBP–SulA by Lon, while other amino acids did not. These results suggest that the histidine residue at the extreme C-terminus of SulA is recognized specifically by Lon, leading to a high-affinity interaction between SulA and Lon.

IN VIVO SELECTIVITY BETWEEN HYPOTENSIVE AND PLATELET ANTIAGGREGATING ACTIONS OF ILOPROST AND PGI2 IN BEAGLE DOGS

1987 ◽  
Author(s):  
F Hermán ◽  
P Hadházy ◽  
K Magyar
Keyword(s):  
Blood Pressure ◽  
Platelet Aggregation ◽  
Arterial Blood Pressure ◽  
Bolus Administration ◽  
Beagle Dogs ◽  
Duration Of Action ◽  
Arterial Blood ◽  
Level Of Significance

Iloprost (Schering A.G.) is a chemically stable derivative of prostacyclin. We compared the hypotensive and antiaggregatory effects of PGI2 and Iloprost. The concentration producing 50% inhibition (IC50) of ADP-induced platelet aggregation in vitro was 0.35±0.15 nmol/1 for PGI2 and 0.56±0.2 nmol/1 for Iloprost (n=5). The in vivo antiaggregatory activity was measured with a modified filtration pressure technique (F.Hermán et al.Thromb. Res.44 /1986/, 575) in anaesthetized beagle dogs; the change in arterial blood pressure was recorded simultaneously. Using this technique, the dose-response relationship and the duration of action of prostacyclin and Iloprost following bolus administration have been determined. PGI2 was equipotent with Iloprost in inhibiting platelet aggregation in vivo (ED25: 0.25±0.04 nmol/kg; 0.28±0.05 respectively). At the same time PGI2 was two times as potent as Iloprost in decreasing the mean arterial blood pressure (ED25: 0.41±0.12 nmol/kg; 0.87±0.14 nmol/kg respectively). The antiaggregatory and hypotensive effects of Iloprost last longer in each experiment than that of PGI2, but did not reach the level of significance probably due to the considerable interindividual differences. The in vivo selectivity ratios (hypotensive potency/antiaggregatory potency) of Iloprost and PGI2 were 0.32 and 0.6 respectively. These results show that in anesthetized beagles Iloprost is somewhat more selective than PGI2 in inhibiting platelet aggregation.

scholarly journals Crustacean hyperglycaemic hormone (CHH)-like peptides and CHH-precursor-related peptides from pericardial organ neurosecretory cells in the shore crab, Carcinus maenas, are putatively spliced and modified products of multiple genes

2001 ◽  
Vol 356 (1) ◽  
pp. 159-170 ◽  
Author(s):  
Heinrich DIRCKSEN ◽  
Detlef BÖCKING ◽  
Uwe HEYN ◽  
Christa MANDEL ◽  
J. Sook CHUNG ◽  
...  
Keyword(s):  
Signal Peptide ◽  
Carcinus Maenas ◽  
Penaeid Shrimp ◽  
Neurosecretory Cells ◽  
Shore Crab ◽  
Amino Acid Peptide ◽  
C Terminus ◽  
Gene Structures

About 24 intrinsic neurosecretory neurons within the pericardial organs (POs) of the crab Carcinus maenas produce a novel crustacean hyperglycaemic hormone (CHH)-like peptide (PO-CHH) and two CHH-precursor-related peptides (PO-CPRP I and II) as identified immunochemically and by peptide chemistry. Edman sequencing and MS revealed PO-CHH as a 73 amino acid peptide (8630Da) with a free C-terminus. PO-CHH and sinus gland CHH (SG-CHH) share an identical N-terminal sequence, positions 1–40, but the remaining sequence, positions 41–73 or 41–72, differs considerably. PO-CHH may have different precursors, as cDNA cloning of PO-derived mRNAs has revealed several similar forms, one exactly encoding the peptide. All PO-CHH cDNAs contain a nucleotide stretch coding for the SG-CHH41–76 sequence in the 3′-untranslated region (UTR). Cloning of crab testis genomic DNA revealed at least four CHH genes, the structure of which suggest that PO-CHH and SG-CHH arise by alternative splicing of precursors and possibly post-transcriptional modification of PO-CHH. The genes encode four exons, separated by three variable introns, encoding part of a signal peptide (exon I), the remaining signal peptide residues, a CPRP, the PO-CHH1–40/SG-CHH1–40 sequences (exon II), the remaining PO-CHH residues (exon III) and the remaining SG-CHH residues and a 3′-UTR (exon IV). Precursor and gene structures are more closely related to those encoding related insect ion-transport peptides than to penaeid shrimp CHH genes. PO-CHH neither exhibits hyperglycaemic activity in vivo, nor does it inhibit Y-organ ecdysteroid synthesis in vitro. From the morphology of the neurons it seems likely that novel functions remain to be discovered.

scholarly journals The PEST-like sequence of I kappa B alpha is responsible for inhibition of DNA binding but not for cytoplasmic retention of c-Rel or RelA homodimers.

1995 ◽  
Vol 15 (2) ◽  
pp. 872-882 ◽  
Author(s):  
M K Ernst ◽  
L L Dunn ◽  
N R Rice
Keyword(s):  
Amino Acid ◽  
Dna Binding ◽  
Direct Interaction ◽  
Terminal Region ◽  
Nf Kappa B ◽  
I Kappa B Alpha ◽  
Functional Capabilities ◽  
C Terminus

In most cells, proteins belonging to the Rel/NF-kappa B family of transcription factors are held in inactive form in the cytoplasm by an inhibitor protein, I kappa B alpha. Stimulation of the cells leads to degradation of the inhibitor and transit of active DNA-binding Rel/NF-kappa B dimers to the nucleus. I kappa B alpha is also able to inhibit DNA binding by Rel/NF-kappa B dimers in vitro, suggesting that it may perform the same function in cells when the activating signal is no longer present. Structurally, the human I kappa B alpha molecule can be divided into three sections: a 70-amino-acid N terminus with no known function, a 205-residue midsection composed of six ankyrin-like repeats, and a very acidic 42-amino-acid C terminus that resembles a PEST sequence. In this study we examined how the structural elements of the I kappa B alpha protein correlate with its functional capabilities both in vitro and in vivo. Using a battery of I kappa B alpha mutants, we show that (i) a dimer binds a single I kappa B alpha molecule, (ii) the acidic C-terminal region of I kappa B alpha is not required for protein-protein binding and does not mask the nuclear localization signal of the dimer, (iii) the same C-terminal region is required for inhibition of DNA binding, and (iv) this inhibition may be accomplished by direct interaction between the PEST-like region and the DNA-binding region of one of the subunits of the dimer.

A 113-amino-acid truncation at the NS1 C-terminus is a determinant for viral replication of H5N6 avian influenza virus in vitro and in vivo

2018 ◽  
Vol 225 ◽  
pp. 6-16 ◽  
Author(s):  
Xiaole Cui ◽  
Yanhong Ji ◽  
Zhengxiang Wang ◽  
Yingying Du ◽  
Haoran Guo ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Amino Acid ◽  
Avian Influenza ◽  
Viral Replication ◽  
Avian Influenza Virus ◽  
C Terminus

Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide

1995 ◽  
Vol 269 (1) ◽  
pp. H326-H331 ◽  
Author(s):  
R. R. Brandt ◽  
D. M. Heublein ◽  
L. L. Aarhus ◽  
J. A. Lewicki ◽  
J. C. Burnett
Keyword(s):  
Natriuretic Peptide ◽  
Clearance Rate ◽  
Metabolic Clearance ◽  
Binding Assays ◽  
Metabolic Clearance Rate ◽  
Amino Acid Peptide ◽  
Cardiovascular Actions ◽  
Clearance Receptor

C-type natriuretic peptide (CNP) is a newly described 22-amino acid peptide of endothelial cell origin, which has selective cardiovascular actions and is structurally related to atrial natriuretic peptide (ANP). Recent in vitro studies have demonstrated that an important regulatory pathway for the clearance of natriuretic peptides involves binding to a common clearance receptor [natriuretic peptide C receptor (NPR-C)]. Although CNP has also been identified as a ligand for NPR-C in binding assays, no studies have defined the in vivo interaction of CNP with NPR-C. CNP (10 ng.kg-1.min-1) followed by C-ANP-(4-23), a specific ligand for NPR-C blockade, was infused intravenously in two groups (both n = 7) of anesthetized dogs at two different doses (0.1 or 1.0 micrograms.kg-1.min-1) to permit calculation of total metabolic clearance rate (TMCR). C-ANP-(4-23) increased circulating CNP and reduced TMCR in both groups. Pulmonary metabolic clearance rate was negative at baseline, suggesting a net secretion of CNP across the lung, which was increased during CNP infusion and was abolished with NPR-C blockade. Renal and femoral metabolic clearance rates were positive at baseline and increased with CNP infusion. A decrease in cardiac output and cardiac filling pressures in response to CNP administration was potentiated by NPR-C blockade. We conclude that 1) circulating CNP achieved by CNP infusion is regulated by NPR-C in vivo, 2) the pulmonary circulation is a possible site of CNP secretion, 3) the renal and peripheral circulations are sites of CNP clearance, and 4) NPR-C blockade potentiates the selective cardiovascular actions of CNP.

Alphastatin, a 24–amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo

Blood ◽  
2004 ◽  
Vol 103 (2) ◽  
pp. 601-606 ◽  
Author(s):  
Carolyn A. Staton ◽  
Nicola J. Brown ◽  
Gary R. Rodgers ◽  
Kevin P. Corke ◽  
Simon Tazzyman ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Amino Acid ◽  
Growth Factor ◽  
Detectable Effect ◽  
Tubule Formation ◽  
Human Fibrinogen ◽  
Amino Acid Peptide ◽  
Normal Tissues

Abstract Angiogenesis, the development of new blood vessels from existing vasculature, is crucial for the development and metastasis of solid tumors. Here, we show for the first time that a 24–amino acid peptide derived from the amino terminus of the alpha chain of human fibrinogen (termed “alphastatin”) has potent antiangiogenic properties, inhibiting both the migration and tubule formation of human dermal microvascular endothelial cells in response to vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF) in vitro. Moreover, alphastatin markedly inhibits the growth of tumors in a syngeneic murine model. Tumors from mice receiving daily injections of alphastatin for 12 days exhibited large areas of intravascular disruption and thrombosis with substantial cellular necrosis. Importantly, alphastatin administration had no detectable effect on vessels in such normal tissues as liver, lungs, and kidney. Taken together, these data indicate that alphastatin is a potent new antiangiogenic agent in vitro and antivascular agent in vivo.

A C TYPE NATRIURETIC PEPTIDE IS A VASODILATOR IN VIVO AND IN VITRO IN THE COMMON DOGFISH

1992 ◽  
Vol 133 (2) ◽  
pp. R1-R4 ◽  
Author(s):  
C. Bjenning ◽  
Y. Takei ◽  
T.X. Watanabe ◽  
K. Nakajima ◽  
S. Sakakibara ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Arterial Blood Pressure ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Physiological Role ◽  
Arterial Blood ◽  
Brain Natriuretic Peptides ◽  
Dose Dependent

ABSTRACT The effects of an elasmbranch cardiac C-type natriuretic peptide (dogfish CNP-22) on arterial blood pressure were investigated in vivo in chronically cannulated dogfish Scyliorhinus canicula and in vitro by a myographic technique using the distal part of the first branchial artery. In-vivo dogfish CNP-22 caused a dose-dependent reduction in mean arterial blood pressure which was much more potent than that of α-human ANP. In-vitro dogfish CNP-22 also caused a dose-dependent relaxation which was independent of the endothelium. These results are in marked contrast to those obtained in similar studies on other vertebrate species in which CNP exhibited only mild hypotensive effects compared to both atrial and brain natriuretic peptides. This study indicates the importance of using homologous peptides in determing the physiological role of natriuretic peptides in non-mammalian vertebrates.

scholarly journals Development of an intracellularly acting inhibitory peptide selective for PKN

2009 ◽  
Vol 425 (2) ◽  
pp. 445-543 ◽  
Author(s):  
Kazuhiro Shiga ◽  
Kentaro Takayama ◽  
Shiroh Futaki ◽  
Jessica E. Hutti ◽  
Lewis C. Cantley ◽  
...  
Keyword(s):  
Amino Acid ◽  
Catalytic Domain ◽  
Phosphorylation Site ◽  
Coiled Coil ◽  
Terminal Region ◽  
Inhibitory Peptide ◽  
Amino Acid Peptide ◽  
Amino Acid Stretch

PKNs form a subfamily of the AGC serine/threonine protein kinases, and have a catalytic domain homologous with that of PKC (protein kinase C) in the C-terminal region and three characteristic ACC (antiparallel coiled-coil) domain repeats in the N-terminal region. The preferred peptide phosphorylation motif for PKNs determined by a combinatorial peptide library method was highly similar to that of PKCs within a 10-amino-acid stretch. Previously reported PKN inhibitory compounds also inhibit PKCs to a similar extent, and no PKN selective inhibitors have been commercially available. We have identified a 15-amino-acid peptide inhibitor of PKNs based on amino acids 485–499 of the C-terminal region of the C2-like domain of PKN1. This peptide, designated as PRL, selectively inhibits the kinase activity of all isoforms of PKN (Ki=0.7 μM) towards a peptide substrate, as well as autophosphorylation activity of PKN in vitro, in contrast with PKC. Reversible conjugation by a disulfide bond of a carrier peptide bearing a penetration accelerating sequence to PRL, facilitated the cellular uptake of this peptide and significantly inhibited phosphorylation of tau by PKN1 at the PKN1-specific phosphorylation site in vivo. This peptide may serve as a valuable tool for investigating PKN activation and PKN-mediated responses.

Sign in / Sign up

Export Citation Format

Share Document